Anti-Obesity Agents

"Anti-Obesity Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.

Descriptor ID	D019440
MeSH Number(s)	D27.505.954.427.140
Concept/Terms	Anti-Obesity Agents Anti-Obesity Agents Agents, Anti-Obesity Anti Obesity Agents Anti-Obesity Drugs Anti Obesity Drugs Drugs, Anti-Obesity Antiobesity Drugs Drugs, Antiobesity Antiobesity Agents Agents, Antiobesity Weight-Loss Agents Weight-Loss Agents Agents, Weight-Loss Weight Loss Agents Weight-Loss Drugs Drugs, Weight-Loss Weight Loss Drugs

Below are MeSH descriptors whose meaning is more general than "Anti-Obesity Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Central Nervous System Agents [D27.505.954.427]
Anti-Obesity Agents [D27.505.954.427.140]

Below are MeSH descriptors whose meaning is related to "Anti-Obesity Agents".

Below are MeSH descriptors whose meaning is more specific than "Anti-Obesity Agents".

Anti-Obesity Agents
Appetite Depressants

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Anti-Obesity Agents" by people in this website by year, and whether "Anti-Obesity Agents" was a major or minor topic of these publications.

Bar chart showing 23 publications over 17 distinct years, with a maximum of 2 publications in 2005 and 2009 and 2010 and 2011 and 2013 and 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	1	0	1
2000	1	0	1
2003	1	0	1
2004	0	1	1
2005	2	0	2
2007	0	1	1
2009	0	2	2
2010	1	1	2
2011	2	0	2
2012	1	0	1
2013	2	0	2
2015	0	1	1
2016	1	1	2
2018	0	1	1
2019	1	0	1
2022	1	0	1
2024	1	0	1

Below are the most recent publications written about "Anti-Obesity Agents" by people in Profiles.

Pan XH, Tan B, Chin YH, Lee ECZ, Kong G, Chong B, Kueh M, Khoo CM, Mehta A, Majety P, Grandhi GR, Dimitriadis GK, Foo R, Chew NWS, Le Roux CW, Mamas MA, Chan MY. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obesity (Silver Spring). 2024 05; 32(5):840-856.

View in: PubMed
Kyrillos J. Semaglutide 2.4-mg injection as a novel approach for chronic weight management. Am J Manag Care. 2022 12; 28(15 Suppl):S297-S306.

View in: PubMed
Ritchey ME, Harding A, Hunter S, Peterson C, Sager PT, Kowey PR, Nguyen L, Thomas S, Cainzos-Achirica M, Rothman KJ, Andrews EB, Anthony MS. Cardiovascular Safety During and After Use of Phentermine and Topiramate. J Clin Endocrinol Metab. 2019 02 01; 104(2):513-522.

View in: PubMed
Jabbour SA, Fr?as JP, Guja C, Hardy E, Ahmed A, ?hman P. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes Obes Metab. 2018 06; 20(6):1515-1519.

View in: PubMed
Lunsford KE, Bodzin AS, Reino DC, Wang HL, Busuttil RW. Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation. World J Gastroenterol. 2016 Dec 07; 22(45):10071-10076.

View in: PubMed
Legro RS, Dodson WC, Kunselman AR, Stetter CM, Kris-Etherton PM, Williams NI, Gnatuk CL, Estes SJ, Allison KC, Sarwer DB, Diamond MP, Schlaff WD, Casson PR, Christman GM, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Zhang H, Eisenberg E, Coutifaris C, Dokras A. Benefit of Delayed Fertility Therapy With Preconception Weight Loss Over Immediate Therapy in Obese Women With PCOS. J Clin Endocrinol Metab. 2016 07; 101(7):2658-66.

View in: PubMed
Dietz WH, Baur LA, Hall K, Puhl RM, Taveras EM, Uauy R, Kopelman P. Management of obesity: improvement of health-care training and systems for prevention and care. Lancet. 2015 Jun 20; 385(9986):2521-33.

View in: PubMed
Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014 Jan; 95(1):53-66.

View in: PubMed
Kim GW, Lin JE, Blomain ES, Waldman SA. New advances in models and strategies for developing anti-obesity drugs. Expert Opin Drug Discov. 2013 Jun; 8(6):655-71.

View in: PubMed
Colon-Gonzalez F, Kim GW, Lin JE, Valentino MA, Waldman SA. Obesity pharmacotherapy: what is next? Mol Aspects Med. 2013 Feb; 34(1):71-83.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement